Latest Conference Articles

Imran Satia, MD, PhD, discusses promising phase 2A trial data showing quick and significant improvements in patients' perception of cough frequency and severity.

Hanania discusses the pooled BOREAS and NOTUS post hoc data showing dupilumab protects lung function before and after COPD exacerbations.

View slated expert interviews and 6 clinical GI, hepatology, and endoscopy trials to watch at ACG 2025.

Despite clinical definitions suggesting patients recover from exacerbations within 2 weeks of hospital discharge, most patients in a qualitative survey believed they had not achieved recovery within 3 months.

Evidence-based guidelines from emphasize personalized transfusion strategies for critically ill patients, urging clinicians to avoid routine platelet and fresh frozen plasma transfusions during common procedures.

Wood shares 3 factors that influencing our nationally poor rates of high-risk lung cancer screening.

McCormack believes simple lung function results accrued over a lifetime can optimize an individual's pulmonary care.

Retrospective cohort data at CHEST 2025 show the similar efficacy profiles — but slightly different safety outcomes — among patients receiving either biologic.

Most clinicians are not considering poor home air exposure when treating persistent asthma or airway disease, Raju explains. That may be making a difference in outcomes.

Rali highlights a series of randomized, controlled trials that could reinvigorate the recently stagnant field of PE treatment development.

Ezekowitz spotlights improvement in cardiovascular mortality and heart failure hospitalization despite a failure to achieve the primary endpoint of VICTOR.

Witteles highlights the uniform improvement after the tafamidis and vutrisiran arms were both moved to the same vutrisiran dose.

An exploratory analysis of the ATTRibute-CM trial spotlighted acoramidis’s superior efficacy in lowering CVD-related risks versus placebo.

This interview segment with Irvine highlighted his team’s data presented at EADV regarding children 6-11 years with atopic dermatitis on dupilumab.

In this interview, improvements observed in children 6-11 years with severe atopic dermatitis following dupilumab use were spotlighted.

Desai details recent advancements in medicine and invasive treatments while reminding clinicians of what can still be done to protect patients.

In this segment of her EADV interview, Markowitz highlights 3-D imaging data from the DISCOVER study on dupilumab (Dupixent) and atopic dermatitis in skin of color.

This EADV interview features a discussion of data from the DISCOVER study on the effects of dupilumab (Dupixent) on atopic dermatitis in skin of color.

Cedars discusses the difficulties in diagnosing heart failure in this population and how clinicians can provide their patients with better care.

This interview from EADV highlights recent data from PRIME and PRIME2 on the effects of dupilumab (Dupixent) on itch and pain in prurigo nodularis.

A prespecified secondary analysis revealed no difference in male and female patients’ responses to tirzepatide in obesity-related HFpEF.

Peters emphasized how the new findings reinforce treatment strategies for chronic rhinosinusitis with nasal polyps.

Bhatt discussed the latest data from a post-hoc analysis of the BOREAS and NOTUS trials.

Read about groundbreaking FDA decisions, exciting new heart failure research, and more.

This set of interviews collects perspectives from 11 leading clinicians in the heart failure field, cataloguing the biggest news from 2025.

Counting down the most impactful news at major medical meetings, it’s the HCPLive Five! This episode focuses on 5 key dermatology updates from EADV.

During this EADV interview, Lebwohl speaks to some of the most recent developments in the psoriasis research space.

Hanania discussed the rationale and findings of the BOREAS and NOTUS studies.